These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11267946)

  • 1. Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
    Shimamoto Y; Fujioka A; Kazuno H; Murakami Y; Ohshimo H; Kato T; Matsuda A; Sasaki T; Fukushima M
    Jpn J Cancer Res; 2001 Mar; 92(3):343-51. PubMed ID: 11267946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil.
    Takatori S; Kanda H; Takenaka K; Wataya Y; Matsuda A; Fukushima M; Shimamoto Y; Tanaka M; Sasaki T
    Cancer Chemother Pharmacol; 1999; 44(2):97-104. PubMed ID: 10412942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.
    Kazuno H; Fujioka A; Fukushima M; Wataya Y; Matsuda A; Sasaki T
    Int J Oncol; 2009 May; 34(5):1373-80. PubMed ID: 19360349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.
    Hattori H; Tanaka M; Fukushima M; Sasaki T; Matsuda A
    J Med Chem; 1996 Dec; 39(25):5005-11. PubMed ID: 8960561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic mechanisms of new antitumor nucleoside analogues, 3'-ethynylcytidine (ECyd) and 3'-ethynyluridine (EUrd).
    Kanda H; Takatori S; Matsuda A; Sasaki T; Tanaka M; Fukushima M; Wataya Y
    Nucleic Acids Symp Ser; 1997; (37):137-8. PubMed ID: 9586037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
    Kazuno H; Sakamoto K; Fujioka A; Fukushima M; Matsuda A; Sasaki T
    Cancer Sci; 2005 May; 96(5):295-302. PubMed ID: 15904471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)1: antitumor effect and mechanism of action.
    Azuma A; Matsuda A; Sasaki T; Fukushima M
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):609-19. PubMed ID: 11563078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of a new antitumor ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil.
    Kazuno H; Shimamoto Y; Tsujimoto H; Fukushima M; Matsuda A; Sasaki T
    Oncol Rep; 2007 Jun; 17(6):1453-60. PubMed ID: 17487404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antitumor effect and mechanism of a novel multifunctional nucleoside, 3'-ethynylnucleoside, on human cancers].
    Tanaka M; Tabata S; Matsuda A; Fukushima M; Eshima K; Sasaki T
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):476-82. PubMed ID: 9063487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.
    Shimamoto Y; Koizumi K; Okabe H; Kazuno H; Murakami Y; Nakagawa F; Matsuda A; Sasaki T; Fukushima M
    Jpn J Cancer Res; 2002 Jul; 93(7):825-33. PubMed ID: 12149149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
    Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
    Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and biochemical mechanisms of the resistance of human cancer cells to a new anticancer ribo-nucleoside, TAS-106.
    Shimamoto Y; Kazuno H; Murakami Y; Azuma A; Koizumi K; Matsuda A; Sasaki T; Fukushima M
    Jpn J Cancer Res; 2002 Apr; 93(4):445-52. PubMed ID: 11985795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PK-PD modeling of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and the enhanced antitumor effect of its phospholipid derivatives in long-circulating liposomes.
    Takada A; Kamiya H; Shuto S; Matsuda A; Harashima H
    Int J Pharm; 2009 Jul; 377(1-2):52-9. PubMed ID: 19426792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and -uracil1.
    Hattori H; Nozawa E; Iino T; Yoshimura Y; Shuto S; Shimamoto Y; Nomura M; Fukushima M; Tanaka M; Sasaki T; Matsuda A
    J Med Chem; 1998 Jul; 41(15):2892-902. PubMed ID: 9667977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new antitumor nucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd), is a potent inhibitor of RNA synthesis.
    Matsuda A; Fukushima M; Wataya Y; Sasaki T
    Nucleosides Nucleotides; 1999; 18(4-5):811-4. PubMed ID: 10432683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic mechanism of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd).
    Wataya Y; Takenaka K; Yokogawa T; Matsuda A; Sasaki T; Fukushima M
    Nucleic Acids Symp Ser; 1999; (42):133-4. PubMed ID: 10780415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer mechanisms of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd, TAS-106).
    Naito T; Yokogawa T; Kim HS; Futagami M; Wataya Y; Matsuda A; Fukushima M; Kitade Y; Sasaki T
    Nucleic Acids Res Suppl; 2002; (2):241-2. PubMed ID: 12903195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.
    Lui VW; Lau CP; Cheung CS; Ho K; Ng MH; Cheng SH; Hong B; Tsao SW; Tsang CM; Lei KI; Yamasaki Y; Mita A; Chan AT
    Biochem Pharmacol; 2010 Jun; 79(12):1772-80. PubMed ID: 20219441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Yokogawa T; Okabe H; Kitazato K
    Int J Mol Med; 2004 Feb; 13(2):249-55. PubMed ID: 14719131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.